International Clinical Trial: Iparomlimab and Tuvonralimab combined with docetaxel and stereotactic body radiotherapy for advanced non-small cell lung cancer with driver gene negativity that have progressed after PD-(L)1 inhibitor treatment: A prospective, single-arm, phase II clinical study

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122045) titled 'Iparomlimab and Tuvonralimab combined with docetaxel and stereotactic body radiotherapy for advanced non-small cell lung cancer with driver gene negativity that have progressed after PD-(L)1 inhibitor treatment: A prospective, single-arm, phase II clinical study' on April 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: chongqing university cancer hospital

Condition: Advanced non-small cell lung cancer

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2026-03-25

Target Sample Size: Experimental group:35;

Countries of Recruitment: China

To know more, vi...